期刊
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
卷 107, 期 34, 页码 15081-15086出版社
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1009575107
关键词
nuclear receptor corepressor; mammary epithelial cells; mammospheres; tumor suppressor protein; tamoxifen therapy
资金
- National Cancer Institute [CA079911]
- Susan G. Komen for the Cure Foundation [BCTR0600180]
- Jayne & Phil Hubbell Family and Roswell Park Alliance Foundation
- National Institutes of Health [T32 CA059268, 2T32CA009072]
- Robert Bosch Foundation Stuttgart
- National Cancer Institute Cancer Center [CA016056]
Estrogen receptor alpha (ER alpha) plays an important role in the onset and progression of breast cancer, whereas p53 functions as a major tumor suppressor. We previously reported that ER alpha binds to p53, resulting in inhibition of transcriptional regulation by p53. Here, we report on the molecular mechanisms by which ER alpha suppresses p53's transactivation function. Sequential ChIP assays demonstrated that ER alpha represses p53-mediated transcriptional activation in human breast cancer cells by recruiting nuclear receptor core-pressors (NCoR and SMRT) and histone deacetylase 1 (HDAC1). RNAi-mediated down-regulation of NCoR resulted in increased endogenous expression of the cyclin-dependent kinase (CDK)inhibitor p21(Waf1/Cip1) (CDKN1A) gene, a prototypic transcriptional target of p53. While 17 beta-estradiol (E2) enhanced ER alpha binding to p53 and inhibited p21 transcription, antiestrogens decreased ER alpha recruitment and induced transcription. The effects of estrogen and antiestrogens on p21 transcription were diametrically opposite to their known effects on the conventional ERE-containing ER alpha target gene, pS2/TFF1. These results suggest that ER alpha uses dual strategies to promote abnormal cellular proliferation: enhancing the transcription of ERE-containing proproliferative genes and repressing the transcription of p53-responsive antiproliferative genes. Importantly, ER alpha binds to p53 and inhibits transcriptional activation by p53 in stem/progenitor cell-containing murine mammospheres, suggesting a potential role for the ER-p53 interaction in mammary tissue homeostasis and cancer formation. Furthermore, retrospective studies analyzing response to tamoxifen therapy in a subset of patients with ER-positive breast cancer expressing either wild-type or mutant p53 suggest that the presence of wild-type p53 is an important determinant of positive therapeutic response.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据